Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: A REPLACE-2 substudy

Journal of the American College of Cardiology

Volumn 44, Issue 6, 2004, Pages 1194-1199

  Saw, Jacqueline ^a   Lincoff, A Michael ^a   Desmet, Walter ^b   Betriu, Amadeo ^c   Rutsch, Wolfgang ^d   Wilcox, Robert G ^e   Kleiman, Neil S ^f   Wolski, Kathy ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PYRIDINE DERIVATIVE; THIENOPYRIDINE; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 4444287645     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.049     Document Type: Article

References (11)

1. S. Steinhubl, S. Ellis, K. Wolski, A. Lincoff, E. Topol Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial Circulation 103 2001 1403 1409
2. S. Mehta, S. Yusuf, R Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
3. S. Steinhubl, P. Berger, J Mann Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention JAMA 288 2002 2411 2420
4. E. Topol, D. Moliterno, H Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
5. A. Lincoff, J. Bittl, R Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention JAMA 289 2003 853 863
6. J. Weitz, H. Buller Direct thrombin inhibitors in acute coronary syndrome: present and future Circulation 105 2002 1004 1011
7. R. Kumar, S. Beguin, H. Hemker The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity Thromb Haemost 74 1995 962 968
8. L.D. Brace, S. Issleib, J. Fareed Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway Thromb Res 39 1985 533 537
9. A. Kastrati, J. Mehilli, H Schuhlen A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238
10. I. Muller, M. Seyfarth, S Rudiger Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93
11. Steinhubl S, Darrah S, Brennan D, McErlean E, Berger P, Topol E. Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial (abstr). Circulation 2003;108:IV374.